Accumetrics develops and markets the VerifyNow System, a point-of-care platform that measures platelet reactivity to major antiplatelet therapies including aspirin, P2Y12 inhibitors and GP IIb/IIIa inhibitors. The VerifyNow System is widely used in clinical settings where antiplatelet medications are prescribed to reduce future thrombotic events such as heart attack and stroke. The company reported an additional $7M raised in an ongoing financing round, bringing the round total to $24M. The capital infusion came primarily from existing investors. Accumetrics intends to use the funds to complete a number of key milestones and to continue expanding its global commercialization efforts. No operating metrics beyond the financing were disclosed in the article.

Total raised

$7M

Funding rounds

1

Latest round

Equity

Latest activity

Sep 2010